Prophylactic or therapeutic agents for diseases associated with dysfunction of NOS

Abstract

It is an object of the present invention to provide a therapeutic agent for effectively preventing or ameliorating diseases caused by dysfunction of NOS. The present invention provides a pharmaceutical composition for preventing and/or treating diseases associated with dysfunction of NOS, comprising as an effective ingredient, a compound of the formula (I): wherein R 1 and R 2 each represents a hydrogen atom or, taken together with each other, represent a single bond, while R 3 represents —CH(OH)CH(OH)CH 3 , —CH(OCOCH 3 )CH(OCOCH 3 )CH 3 , —CH 3 , —CH 2 OH, or a phenyl group when R 1 and R 2 each represents a hydrogen atom, or —COCH(OH)CH 3 when R 1 and R 2 together represent a single bond, or a pharmaceutically acceptable salt thereof.

1 . A pharmaceutical composition for preventing or treating diseases associated with dysfunction of NOS, comprising as an effective ingredient, a compound of the formula (I):  
       
         
           
           
               
               
           
         
       
       wherein R 1  and R 2  each represents a hydrogen atom or, taken together with each other, represent a single bond, while R 3  represents —CH(OH)CH(OH)CH 3 , —CH(OCOCH 3 )CH(OCOCH 3 )CH 3 , —CH 3 , —CH 2 OH, or a phenyl group when R 1  and R 2  each represents a hydrogen atom, or —COCH(OH)CH 3  when R 1  and R 2  together represent a single bond, or a pharmaceutically acceptable salt thereof:  
     
     
         2 . The prophylactic or therapeutic agent of  claim 1 , wherein the disease associated with dysfunction of NOS is a disease accompanied by decreased endogenous NO production.  
     
     
         3 . The prophylactic or therapeutic agent of  claim 1 , wherein the disease associated with dysfunction of NOS is a disease accompanied by dysfunction of endothelial cells.  
     
     
         4 . The prophylactic or therapeutic agent of  claim 1 , wherein the disease associated with dysfunction of NOS is associated with a decrease in NOS expression.  
     
     
         5 . The prophylactic or therapeutic agent of any one of claims  1 ,  2 ,  3  or  4  wherein R 3  is L-erythro-CH(OH)CH(OH)CH 3 .  
     
     
         6 . The prophylactic or therapeutic agent of any one of  claims 1  to  5  which is a prophylactic or therapeutic agent for hypertension.  
     
     
         7 . The prophylactic or therapeutic agent of any one of  claims 1  to  5  which is a prophylactic or therapeutic agent for renal disorders.